Proteinuria Clinical Trial
Official title:
An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka
1. We hypothesise that CKDu patients will have increased arterial stiffness and thus
increased all-cause and cardiovascular mortality. The first objective of this study is
to recruit a cohort of ~ 50 CKDu patients who attend the CKDu clinic in Anuradhapura,
and measure their arterial stiffness using the TensioMed® Arteriographâ„¢ (details below).
We will recruit an age, sex and blood pressure matched control group of healthy Sri
Lankans (consenting visitors with patients both to clinic and as inpatients), and if
possible, a second control group, similarly age, sex and blood pressure matched, who
have CKD of known causes and attend general renal clinic in Anuradhapura.
2. We hypothesise that detailed renal analysis will give insight into the aetiology of CKDu
in the North Central Province of Sri Lanka. The second objective of the study is to
recruit up to 250 CKDu patients and to characterize their disease profile using analysis
serum and urine renal biomarkers, exosomes, proteomics and DNA adducts.
Chronic kidney disease (CKD) is one of the leading causes of hospital admission, clinic
attendance and mortality in some provinces of Sri Lanka. In central and southern provinces
increased incidence is attributed to type-2 diabetes and hypertension; however, this is not
the case in North Central Province (NCP) where CKD of unknown aetiology (CKDu) is the
commonest diagnosis. A recent World Health Organisation (WHO) investigation concluded that at
least 8,000 people have CKDu2.
First recognized in the early nineties, much work has been done to try to characterise the
disease however results are conflicting. Most suggest male paddy farmers working in rural
areas of the NCP are worst affected, presenting in their fifth decade with end stage renal
failure. However, a recent WHO study revealed higher prevalence in females, although more
severe renal impairment was more common in men.
Risk factors include inhabiting NCP > five years, inhabiting the 'dry zone', reduced BMI,
lower socio-economic class, and exposure to agrochemicals. There has been suggestion of a
genetic link although positive family history is limited to one generation, with no evidence
of mendelian progression. Epidemiological studies reveal a clustered geographical
distribution with areas such as Medawachchiya, Padaviya and Girandurukotte most affected.
High prevalence areas encompass a well-developed irrigation system used for agricultural
purposes.
Renal biopsies show tubulointerstitial disease with tubular atrophy, interstitial mononuclear
cell infiltration, interstitial fibrosis but no immune-complex deposition on
immunofluorescence. This supports a toxin-mediated process.
Many aetiologies have been considered including exposure to heavy metals (cadmium, arsenic)
and their chelation by herbicides, fluro-aluminium complexes, agricultural pesticides,
mycotoxins, and herbal medicines. Selenium deficiency and genetic susceptibility may be
predisposing factors. The true aetiology is likely multifactorial.
The multi-system impact of CKDu has yet to be fully realised. Epidemiological and clinical
data show that damage to large arteries contributes to the increased cardiovascular risk
observed in CKD. Atherosclerosis is the most frequent cause of arterial damage but the medial
calcification seen in CKD also leads to arterial stiffening. This stiffening causes elevation
in systolic blood pressure, increasing left ventricular workload with the gradual development
of LVH, and also a fall in diastolic blood pressure impairing coronary blood flow. Arterial
calcification and stiffness are independent predictors of all-cause and cardiovascular
mortality in patients with CKD. Arterial stiffness will be compared in CKDu patients, healthy
Sri Lankan controls and CKD patients both in Sri Lanka and Scotland.
We will perform a prospective observational study of up to 250 patients with CKDu presenting
to renal clinics in Teaching Hospital, Anuradhapura. Patient history, basic anthropometric
measurements, and simple non-invasive tests (e.g. blood pressure and arterial stiffness) will
be performed. Urine, serum and plasma samples will be collected for quantitative PCR, and
further analysis for biomarkers of renal injury, exosomes, proteomics and any DNA-adducts.
Patients will be graded using the WHO CKDu grading system. When a renal biopsy is performed,
a copy of the light microscopy findings will be obtained. Comparisons of interest will be
tested via paired t-tests with statistical significance taken at 5%.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Completed |
NCT05086549 -
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
|
||
Terminated |
NCT04051957 -
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
|
Phase 2 | |
Completed |
NCT02232763 -
Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria
|
Phase 3 | |
Terminated |
NCT02057523 -
Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT00493727 -
Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria
|
N/A | |
Active, not recruiting |
NCT00565396 -
Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3
|
N/A | |
Recruiting |
NCT05759754 -
Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease
|
N/A | |
Withdrawn |
NCT02882373 -
Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury
|
Phase 2 | |
Completed |
NCT02327403 -
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT01773382 -
The Effects of Weight Reduction in IgA Nephropathy
|
N/A | |
Completed |
NCT01029002 -
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT00915200 -
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
|
Phase 2 | |
Withdrawn |
NCT00541619 -
Sympathetic Overactivity in Essential Hypertension
|
N/A | |
Withdrawn |
NCT00392132 -
Impact of Screening Patients With HIV for Kidney Disease
|
||
Terminated |
NCT00001978 -
Determination of Kidney Function
|
||
Recruiting |
NCT05457283 -
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
|
Phase 3 | |
Completed |
NCT04874753 -
The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT02972346 -
Availability Study of ACTH to Treat Children SRNS/SDNS
|
N/A | |
Unknown status |
NCT02256995 -
uChek Pilot Study for Urinalysis in the Antenatal Care Setting
|
N/A |